Immuno-PET imaging and radioimmunotherapy of 64Cu-/177Lu-labeled anti-EGFR antibody in esophageal squamous cell carcinoma model
IH Song, TS Lee, YS Park, JS Lee, BC Lee… - Journal of Nuclear …, 2016 - Soc Nuclear Med
Immuno-PET provides valuable information about tumor location, phenotype, susceptibility
to therapy, and treatment response, especially to targeted radioimmunotherapy. In this study …
to therapy, and treatment response, especially to targeted radioimmunotherapy. In this study …
[HTML][HTML] Immuno-PET imaging based radioimmunotherapy in head and neck squamous cell carcinoma model
IH Song, Y Noh, J Kwon, JH Jung, BC Lee, KI Kim… - Oncotarget, 2017 - ncbi.nlm.nih.gov
The epidermal growth factor receptor (EGFR) is one of the most comprehensively studied
molecular targets in head and neck squamous cell carcinoma (HNSCC). However, inherent …
molecular targets in head and neck squamous cell carcinoma (HNSCC). However, inherent …
Quantitative 89Zr immuno-PET for in vivo scouting of 90Y-labeled monoclonal antibodies in xenograft-bearing nude mice
I Verel, GWM Visser, R Boellaard… - Journal of Nuclear …, 2003 - Soc Nuclear Med
Immuno-PET as a scouting procedure before radioimmunotherapy (RIT) aims at the
confirmation of tumor targeting and the accurate estimation of radiation dose delivery to both …
confirmation of tumor targeting and the accurate estimation of radiation dose delivery to both …
177Lu-Labeled Antibodies for EGFR-Targeted SPECT/CT Imaging and Radioimmunotherapy in a Preclinical Head and Neck Carcinoma Model
Z Liu, T Ma, H Liu, Z Jin, X Sun, H Zhao… - Molecular …, 2014 - ACS Publications
Epidermal growth factor receptor (EGFR) has been well characterized as an important target
for cancer therapy. Immunotherapy based on EGFR-specific antibodies (eg, panitumumab …
for cancer therapy. Immunotherapy based on EGFR-specific antibodies (eg, panitumumab …
A radiopharmaceutical [89Zr] Zr-DFO-nimotuzumab for immunoPET with epidermal growth factor receptor expression in vivo
Y Tang, Y Hu, W Liu, L Chen, Y Zhao, H Ma… - Nuclear Medicine and …, 2019 - Elsevier
Introduction The potential of the positron-emitting zirconium-89 (89 Zr)(t 1/2= 78.4 h) has
been recently reported for immune positron emission tomography (immunoPET) …
been recently reported for immune positron emission tomography (immunoPET) …
Affibody-based PET imaging to guide EGFR-targeted cancer therapy in head and neck squamous cell cancer models
TA Burley, C Da Pieve, CD Martins… - Journal of Nuclear …, 2019 - Soc Nuclear Med
In head and neck squamous cell cancer, the human epidermal growth factor receptor 1
(EGFR) is the dominant signaling molecule among all members of the family. So far …
(EGFR) is the dominant signaling molecule among all members of the family. So far …
PET of EGFR antibody distribution in head and neck squamous cell carcinoma models
Epidermal growth factor receptor (EGFR) is a well-characterized protooncogene that has
been shown to promote tumor progression in solid cancers. Clinical results for EGFR …
been shown to promote tumor progression in solid cancers. Clinical results for EGFR …
Correlating EGFR expression with receptor-binding properties and internalization of 64Cu-DOTA-cetuximab in 5 cervical cancer cell lines
M Eiblmaier, LA Meyer, MA Watson… - Journal of Nuclear …, 2008 - Soc Nuclear Med
The anti–epidermal growth factor receptor (anti-EGFR) antibody cetuximab is clinically
approved for the treatment of EGFR-expressing metastatic colorectal cancer and advanced …
approved for the treatment of EGFR-expressing metastatic colorectal cancer and advanced …
PET of EGFR with 64Cu‐cetuximab‐F(ab′)2 in mice with head and neck squamous cell carcinoma xenografts
LK van Dijk, CB Yim, GM Franssen… - Contrast Media & …, 2016 - Wiley Online Library
Overexpression of the epidermal growth factor receptor (EGFR) is linked to an adverse
outcome in various solid tumors. Cetuximab is an EGFR inhibitor, which in combination with …
outcome in various solid tumors. Cetuximab is an EGFR inhibitor, which in combination with …
Quantitative PET of EGFR expression in xenograft-bearing mice using 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody
Purpose Cetuximab, a chimeric monoclonal antibody targeting epidermal growth factor
receptor (EGFR) on the surface of cancer cells, was approved by the FDA to treat patients …
receptor (EGFR) on the surface of cancer cells, was approved by the FDA to treat patients …